Abstract Library

#4172 Hormonally characterised NF-PanNETs and their clinicopathological features

Introduction: PanNETs show pronounced hormonal heterogeneity. The expression of certain hormones may associate with functional syndromes, but also with histological and genetic features. However, detailed studies of hormonal patterns in PanNETs correlated to morphological and clinical data are lacking.

Conference:

Presenting Author: Moser E

Authors: Moser E, Ito A, Vogel L, Steiger K, Scheidhauer K,

Keywords: Neuroendocrine Tumor, hormonal expression, subtypes, outcome, transcriptional factors,

#3959 Sortilin: A novel marker and potential therapeutic target for functional neuroendocrine tumors

Introduction: A subset of neuroendocrine tumors (NETs) causes a hormone-related disease (functional syndrome); e.g. carcinoid syndrome due to over-secretion of mainly serotonin. Notably, on a molecular level, what distinguishes this subset of functional NETs from nonfunctional tumors is unknown. Furthermore, accurate models of functional NETs are missing. Sortilin, a widely expressed transmembrane receptor, is expressed in many cancer cells, including NETs, and is involved in secretion processes.

Conference:

Presenting Author: Bolduan F

Authors: Bolduan F, Wetzel A, Giesecke Y, Eichhorn I, Alenina N,

Keywords: Neuroendocrine tumor, Functional syndrome, Carcinoid syndrome, Serotonin, Sortilin, Organoids, Enteroendocrine cells,

#3377 Antisecretory effect of oral targeted therapies in advanced functioning neuroendocrine tumors (the ASSET-NET study)

Introduction: Oral targeted therapies (TTs),everolimus and sunitinib,have demonstrated antitumor activity in patients with advanced progressive neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: Perrier M, Walter T, Do Cao C, Coriat R, Haissaguerre M,

Keywords: functional syndrome, targeted therapy, neuroendocrine tumor, antisecretory effect,

#1876 Multiple Endocrine Neoplasia Type 1 (MEN1): The Experience of a Referral Center in Greece

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a genetic disorder involving mainly parathyroid, pituitary and pancreatic neuroendocrine neoplasms (pNENs)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Alexandraki K, Chrysochoou M, Kaltsatou M, Tsoli M, Nikolopoulos G,

Keywords: MEN1,

#27 Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is save and effective. Report of thirty consecutive patients

Introduction: Patients with rapidly progressing neuroendocrine tumors presenting with high tumor load and/or severe clinical syndromes are clinically challenging and with limited life expectany. Peptide receptor radiotherapy (PRRT) and transcatheter arterial chemoembolization (TACE) have demonstrated efficacy in the treatment of neuroendocrine tumors. However, there are no reports that both therapies have been applied in combination.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Hörsch D

Authors: Hörsch D, Gräber C, Prasad V, Gotthardt T, Petrovitch A,

Keywords: PRRT, TACE,